United Therapeutics CFO exercises options, sells shares
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in multiple open‑market transactions.
Rhea-AI Filing Summary
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in multiple open‑market transactions. The sales occurred at weighted average prices within ranges described in the filing, including from $551.68 to $571.72 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, Edgemond directly holds 18,876 shares of United Therapeutics Common Stock.
Positive
- None.
Negative
- None.
Insights
CFO exercised options and sold shares under a pre‑set trading plan.
The filing shows CFO and Treasurer James Edgemond exercised options to acquire 10,000 shares at $135.42 per share, then sold the same number of shares in multiple open‑market trades at prices generally in the mid‑$500s. This is a classic exercise‑and‑sell pattern.
The footnote states the exercise and subsequent sales were made pursuant to a Rule 10b5‑1 trading plan entered on October 31, 2025, indicating the trades were pre‑scheduled rather than timed opportunistically. After these transactions, Edgemond holds 18,876 shares directly, so he retains a meaningful equity stake.
Because the transactions are compensation‑related, conducted under a pre‑arranged plan, and the CFO continues to hold shares, they are typically interpreted as routine liquidity management rather than a clear signal about the company’s prospects.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($4.26M approx. pre-tax spread)
Exercise and Sale
19 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.61M)
Approx. gross sale proceeds
$5.61M
Approx. exercise cost
$1.35M
Approx. pre-tax spread
$4.26M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 40 | $551.8638 | $22K |
| Sale | Common Stock | 401 | $553.9857 | $222K |
| Sale | Common Stock | 778 | $555.2198 | $432K |
| Sale | Common Stock | 844 | $556.1708 | $469K |
| Sale | Common Stock | 977 | $557.0456 | $544K |
| Sale | Common Stock | 720 | $558.1072 | $402K |
| Sale | Common Stock | 240 | $559.028 | $134K |
| Sale | Common Stock | 72 | $560.3911 | $40K |
| Sale | Common Stock | 571 | $561.7471 | $321K |
| Sale | Common Stock | 555 | $562.9975 | $312K |
| Sale | Common Stock | 896 | $563.8634 | $505K |
| Sale | Common Stock | 2,201 | $564.8194 | $1.24M |
| Sale | Common Stock | 742 | $565.9912 | $420K |
| Sale | Common Stock | 323 | $566.8191 | $183K |
| Sale | Common Stock | 400 | $567.95 | $227K |
| Sale | Common Stock | 120 | $569.7467 | $68K |
| Sale | Common Stock | 120 | $571.6533 | $69K |
Holdings After Transaction:
Stock Option — 122,500 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (18)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $561.24 to $562.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $562.40 to $563.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $563.43 to $564.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $564.44 to $565.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $565.50 to $566.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F15. This transaction was executed in multiple trades at prices ranging from $566.53 to $567.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F16. This transaction was executed in multiple trades at prices ranging from $567.64 to $568.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F17. This transaction was executed in multiple trades at prices ranging from $569.14 to $570.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F18. This transaction was executed in multiple trades at prices ranging from $571.53 to $571.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $551.68 to $552.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $553.54 to $554.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $554.58 to $555.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $555.62 to $556.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $556.62 to $557.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $557.75 to $558.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $558.79 to $559.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $560.00 to $560.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 10,000 shares
Option exercise price: $135.42/share
Shares sold: 10,000 shares
+4 more
7 metrics
Options exercised
10,000 shares
Stock options converted to Common Stock on April 2, 2026
Option exercise price
$135.42/share
Exercise price for 10,000 Stock Options
Shares sold
10,000 shares
Total Common Stock sold across 17 open-market trades
Sale price range example
$551.68–$552.02
One disclosed range of weighted average sale prices
Highest disclosed price range
$571.53–$571.72
Upper end of reported multiple-trade price ranges
Shares held after transactions
18,876 shares
Direct Common Stock ownership following April 2, 2026 trades
Rule 10b5-1 plan date
October 31, 2025
Date CFO entered trading plan governing these transactions
Key Terms
Rule 10b5-1 trading plan, stock options, open-market sale, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action: "open-market sale" in multiple non-derivative transactions"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did United Therapeutics (UTHR) CFO James Edgemond do in this Form 4 filing?
United Therapeutics CFO James Edgemond exercised stock options for 10,000 shares and sold 10,000 shares of Common Stock. The transactions were executed in multiple open‑market trades and carried out under a pre‑arranged Rule 10b5‑1 trading plan disclosed in the filing.
What stock options did the United Therapeutics (UTHR) CFO exercise in this Form 4?
James Edgemond exercised stock options covering 10,000 shares of United Therapeutics Common Stock. The options had an exercise price of $135.42 per share and an expiration date of March 15, 2027, converting derivative holdings into directly owned common shares before the subsequent sales.
Were the United Therapeutics (UTHR) CFO’s trades part of a Rule 10b5-1 plan?
Yes. A footnote explains that the option exercise and subsequent sale of shares were conducted under a Rule 10b5‑1 trading plan entered into on October 31, 2025. Such plans pre‑schedule trades, reducing the significance of trade timing as an indicator of insider sentiment.
What is the overall direction of the United Therapeutics (UTHR) CFO’s Form 4 transactions?
The filing combines an option exercise to acquire 10,000 shares with open‑market sales totaling 10,000 shares, resulting in a net sale of shares. However, because the trades were made under a Rule 10b5‑1 plan, they appear as planned liquidity management rather than discretionary market timing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
